Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Coherus BioSciences, Inc. (CHRS) had Revenue of $266.96M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$266.96M
Net Income	$28.51M
Cost of Goods Sold	$117.55M
Gross Profit	$149.41M
Operating Expenses	$378.63M
Operating Income	$-111.67M
Non-Operating Income/Expense	$140.17M
Pre-Tax Income	$28.51M
Normalized Pre-Tax Income	$28.51M
Income after Taxes	$28.51M
Income from Continuous Operations	$28.51M
Consolidated Net Income/Loss	$28.51M
Normalized Income after Taxes	$28.51M
EBIT	$-111.67M
EBITDA	$-106.39M
Weighted-Average Shares Outstanding (Basic)	114.55M
Weighted-Average Shares Outstanding (Diluted)	114.83M
Earnings per Share (EPS) (Basic)	$0.25
Earnings per Share (EPS) (Diluted)	$0.25
Balance Sheet Financials
Current Assets	$341.58M
Property, Plant, and Equipment	$2.84M
Long-Term Assets	$106.95M
Total Assets	$448.53M
Current Liabilities	$282.98M
Long-Term Debt	$264.93M
Long-Term Liabilities	$297.54M
Total Liabilities	$580.52M
Common Equity	$-131.99M
Tangible Shareholders Equity	$-185.64M
Shareholders Equity	$-131.99M
Common Shares Outstanding	115.61M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-20.44M
Cash Flow from Investing Activities	$230.32M
Cash Flow from Financial Activities	$-186.97M
Beginning Cash	$103.34M
End Cash	$126.25M
Increase/Decrease in Cash	$22.91M
Stock-Based Compensation	$27.80M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.99
Debt to Equity Ratio	-2.01
Gross Margin	55.97%
Operating Margin	-41.83%
EBIT Margin	-41.83%
EBITDA Margin	-39.85%
Pre-Tax Profit Margin	10.68%
Profit Margin	10.68%
Free Cash Flow	$-20.44M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.60
Inventory Turnover	1.68
Receiveable Turnover	2.18
Days Sales in Receivables	167.26
Return on Equity	-21.60%
Return on Tangible Equity	-15.36%
Return on Assets	6.36%
Return on Investments	21.44%
Book Value Per Share	$-1.14
Free Cash Flow per Share	$-0.18
Operating Cash Flow per Share	$-0.18

Data from Zacks Investment Research, Inc.